| abstract |
The present invention discloses a method in which TNFα activity is a harmful disease by subcutaneously administering a human antibody which specifically binds human tumor necrosis factor α (hTNFα), preferably a recombinant human antibody. The antibody can be administered with or without methotrexate. These antibodies have high affinity for hTNFα (eg Kd=10-8 M or less), a slow rate of dissociation of hTNFα (eg Koff=10-3 sec-1 or less) and neutralize hTNFα in vitro and in vivo. active. The antibody of the present invention may be a full length antibody or an antigen binding site thereof. The present invention also encompasses a kit comprising a pharmaceutical composition and a pharmaceutical dosage form, and a preloaded syringe containing the pharmaceutical composition. |